News & Events about Harpoon Therapeutics Inc.
Gainers
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.
read more...
Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals? Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals? PR...
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were durable, with many patients on treatment longer ...
Globe Newswire
3 months ago
Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022, from 6:00 p.m. 8:00 p.m. CTSOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Harpoon ...